Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Neil R AggarwalLaurel E BeatyTellen D BennettNichole E CarlsonChristopher B DavisBethany M KwanDavid A MayerToan C OngSeth RussellJeffrey SteeleAdane F WoguMatthew K WyniaRichard D ZaneAdit A GindePublished in: The Journal of infectious diseases (2022)
Real-world evidence demonstrated sotrovimab effectiveness in reducing hospitalization and all-cause 28-day mortality among COVID-19 outpatients during the Delta variant phase.